Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Average (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Equity Average readings, the most recent being $385.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 65.64% year-over-year to $385.7 million, compared with a TTM value of $385.7 million through Dec 2025, up 65.64%, and an annual FY2025 reading of $299.3 million, up 41.51% over the prior year.
  • Equity Average hit $385.7 million in Q4 2025 for Apellis Pharmaceuticals, up from $278.7 million in the prior quarter.
  • The five-year high for Equity Average was $398.3 million in Q2 2022, with the low at -$99.4 million in Q3 2021.
  • Median Equity Average over the past 5 years was $244.7 million (2022), compared with a mean of $225.8 million.
  • The sharpest move saw Equity Average plummeted 158.84% in 2021, then skyrocketed 986.8% in 2022.
  • Year by year, Equity Average stood at $70.7 million in 2021, then soared by 237.7% to $238.6 million in 2022, then decreased by 10.58% to $213.4 million in 2023, then rose by 9.11% to $232.8 million in 2024, then skyrocketed by 65.64% to $385.7 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $385.7 million, $278.7 million, and $160.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.